Mustang Bio Announces Updated Clinical Data on MB-107 Lentiviral Gene Therapy for Patients with X-Linked Severe Combined Immunodeficiency
Mustang Bio, Inc. (MBIO)
Last mustang bio, inc. earnings: 11/12 07:30 am
Check Earnings Report
US:NASDAQ Investor Relations:
mustangbio.com/investor-relations
Company Research
Source: GlobeNewswire
MB-107 preceded by low-dose busulfan conditioning continues to be well tolerated and results in development of functional immune system in newly diagnosed infants with XSCID Enhanced transduction procedure is demonstrating improvements in older patients with XSCID who received prior hematopoietic stem cell transplantation Data presented by St. Jude Children’s Research Hospital and National Institutes of Health at 61st American Society of Hematology Annual Meeting NEW YORK, Dec. 09, 2019 (GLOBE NEWSWIRE) -- Mustang Bio, Inc. (“Mustang”) (NASDAQ: MBIO), a clinical-stage biopharmaceutical company focused on translating today’s medical breakthroughs in cell and gene therapies into potential cures for hematologic cancers, solid tumors and rare genetic diseases, announced today that updated Phase 1/2 clinical data for MB-107 lentiviral gene therapy for X-linked severe combined immunodeficiency (XSCID) were presented on Saturday by St. Jude Children’s Research Hospital (“St. Jude”) and
Show less
Read more
Impact Snapshot
Event Time:
MBIO
Last Price
Price Change
Price Change%
Volume Shares
Max Up
Max Down
%
Volume Ratio
Performance Comparison
Updated
|
Event Day
Stock performance from the time of news release until the following 4pm ET market close
|
Last price at news event
|
Since Event
Multi-day stock performance from the time of the news release
|
|---|---|---|
|
EVENT DAY
Stock performance from the time of news release until the following 4pm ET market close
|
LAST
PRICE AT NEWS EVENT |
SINCE EVENT
Multi-day stock performance from the time of the news release
|
| Last Price | ||
| VWAP | ||
|
High:
|
Max Up |
High:
|
|
Low:
|
Max Down |
Low:
|
|
%
|
Post news range |
%
|
|
|
Price change |
|
|
|
Price Change Percentage |
|
|
|
S&P 500 (SPX) |
|
|
%
|
Volume ratio |
%
|
| Volume | ||
| Ticks | ||
|
|
Avg transaction size |
|
Don't Miss Out On The Next BIG Stock Move
Event day
Event Day Chart will not be displayed beyond 90-day period of the event
Performance since event
Time And Velocity Analysis
Be the first to know
Opt in for alerts from News Quantifed
Sign Up Today
Opt-in for
MBIO alerts
Learn More With NQ
Reading the Impact Report
Help Me Understand This Data
Help Me Understand This Data
How NQ Works
What is news-based trading?
And why is it so successful?
And why is it so successful?
Movers & Shakers
The biggest gainers and losers and WHY it moved
MBIO alerts
High impacting Mustang Bio, Inc. news events
Weekly update
A roundup of the hottest topics
MBIO
News
- Mustang Bio, Inc. (NASDAQ: MBIO) had its price target lowered by analysts at HC Wainwright from $25.00 to $2.00. They now have a "buy" rating on the stock.MarketBeat
- Mustang Bio Announces Closing of $4 Million Public Offering [Yahoo! Finance]Yahoo! Finance
- Mustang Bio Announces Closing of $4 Million Public OfferingGlobeNewswire
- Mustang Bio Announces Pricing of $4 Million Public Offering [Yahoo! Finance]Yahoo! Finance
- Mustang Bio Announces Pricing of $4 Million Public OfferingGlobeNewswire
MBIO
Earnings
- 11/14/23 - Beat
MBIO
Sec Filings
- 5/15/24 - Form 10-Q
- 5/13/24 - Form 424B3
- 5/2/24 - Form 8-K
- MBIO's page on the SEC website